AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$WGS

Stueland Katherine sold $1.0M of WGS

Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 10,501 shares of GeneDx Holdings Corp. (WGS) at an average of $97.61 ($94.26–$99.00, $1.03M total) across 5 trades on 2026-09-16.

Original reporting
SEC EDGAR · Stueland Katherine
Published Sep 18, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WGS
Bearish
medium confidence
Mentioned
$WGS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WGSBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider activity, offering a modest trading signal.

02

Market read

New insider sale may influence short‑term price action for WGS.

03

What to watch

Potential upcoming financing needs or personal tax planning could be driving the sale.

Relevance 6/10Novelty 6/10Timing: filed today

Background

Form 4 filings disclose insider transactions; a CEO sale is noteworthy for investors monitoring insider sentiment.

Company-level read

Ticker impact

$WGSBearishMedium confidence
Context

CEO Katherine Stueland sold 10,501 shares for $1.03M via open‑market transactions on 2026‑09‑16.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size ($1M) is material for a mid‑cap biotech and the insider is the CEO, but no accompanying news explains motive.

Market effects

Sector

May raise concerns for other biotech insiders as a precedent for CEO sell‑offs.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact; only relevant to WGS shareholders.

Counterpoint

What could challenge this read

The sale could be a routine diversification move unrelated to company outlook.

Key entities

  • Company
    GeneDx Holdings Corp.

    Biotech firm listed under ticker WGS.

  • Person
    Katherine Stueland

    Chief Executive Officer of GeneDx Holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WGS insider trading history →

Related articles

MedAI 8/10

GeneDx (WGS) Q2 2026 Earnings Call Transcript

GeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.

aol.com
$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

investing.com
$WGSHighAI 9/10

GeneDx Reports Second Quarter 2026 Financial Results

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of 32% year-over-year • Reported adjusted gross margin (1) of

SEC EDGAR 8-K